摘要
目的：研究多靶点叶酸拮抗剂培美曲塞治疗晚期复发或进展非小细胞肺癌（NSCLC）的有效性和毒性反应。方法：自2006年11月-2007年8月共收集我院30例患者，其中男性21例，女性9例，中位年龄51岁（范围36—71岁）。有组织学及细胞学证实的晚期NSCLC患者，经多次化疗后出现复发或进展，PS评分0～2分。化疗策略：培美曲塞500mg／m^2单药或联合顺铂75mg／m%2，每3周重复；对接受两次或两次以上化疗周期患者进行化疗效果评价。结果：27例可评价疗效，无CR病例，PR1例，SD共16例，PD共10例。全组有效率（CR＋PR）为3．7％（1／27），疾病控制率（CR＋PR＋sD）为62．9％（17／27）。中位生存时间8个月，中位疾病进展时间为2．8个月，1年生存率为31．2％。毒副反应主要为I～Ⅱ度胃肠道反应和骨髓抑制，如恶心、粒细胞减少及贫血。结论：培美曲塞治疗晚期NSCLC安全有效，耐受性好。
Objective： To determine the efficacy and toxicity of pemetrexed in patients with advanced recurrent or progressive non-small cell lung cancer （Nsclc）. Methods： From November 2006 to August 2007, 30 patients were enrolled into this study. Among these patients, 21 were male and 9 were female. The median age was 51 years （ranging from 36 -71 years）. All these patients had been confirmed with pathology or cytology and had failed in previous chemotherapy. PS scale was 0 - 2. Chemotherapy strategy： Single-agent pemetrexed 500mg/m^2 or pemetrexed 500mg/m^2 plus cisplatin 75mg/m^2 （PemCis）. Pemetrexed was given on day I and cisplatin was given on day 2 every 3 weeks. The patient who received two or more cycles was evaluated. Results： 27 patients were evaluated. There was no case with complete response. Only 1 ease got partial response, 16 cases got stable disease and 10 cases got progressive disease. The responsive rate was 3.7% （1/27） and the disease controlling rate was 62.9% （17/27）. The median survival time was 8 months, and the median time for progressive disease was 2.8 months with a 1-year survival rate of 31.2%. The common side effects were Grade I/II gastrointestinal response and hematologic toxicities including nausea, neutropenia and anemia. Conclusion： Pemetrexed had activity and appeared to be well-tolerated in advanced NSCLC.
出处
《军医进修学院学报》
CAS
2009年第1期53-55,共3页
Academic Journal of Pla Postgraduate Medical School
关键词
药物疗法
联合
培美曲塞
癌
非小细胞肺
drug therapy, combination
pemetrexed
carcinoma, non-small cell lung
